Comments
Drug major Ranbaxy, which has been in the eye of the storm for allegedly selling substandard medicines in the US and for unhealthy practices in Europe, got a breather from the Supreme Court on Tuesday.
The apex court rejected a public interest litigation (PIL) calling for a probe against Ranbaxy Laboratories on the grounds that the evidence against the company in India was not substantial.
However, the petitioner M.L. Sharma, has been given permission to file a fresh petition in case he finds evidence against the company.
The bench comprising Justice A.K. Patnaik and Justice Ranjan Gogoi said the court cannot pass a judgment on the company on the basis of the verdict passed by a US court and asked for evidence proving malpractices by the company in India.
A Ranbaxy spokesperson expressed satisfaction with the judgment and said the company is “committed to patient safety and ethical business practices and we will continue to offer high quality drug products to all of our customers in India and worldwide”.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.